Occam Places Leo Wossnig as CTO of LabGenius
Occam’s enduring relationship with LabGenius, a UK-based AI-enabled protein drug discovery platform company, has yielded a second C-suite placement in Leo Wossnig as CTO. Leo will work in close partnership with Gino Van Heeke, the CSO, whom Occam placed as CSO in 2021.
Wossnig comes to LabGenius by way of Odyssey Therapeutics following the acquisition of his company, Rahko, a leading quantum machine learning company which Leo co-founded and led as CEO.
In Wossnig, LabGenius captures an intellectual heavyweight, content expert and accomplished entrepreneur with demonstrated success building and leveraging sophisticated computational technologies in the service of expediting drug discovery at scale
Occam Global is an executive recruiting and leadership advisory firm with specialties across technological fields including Biotech, TechBio, AI-ML, Cell/Gene Therapy, Diagnostics/Genomics, Medical Devices, Research Tools, Digital Health, Alternative Energy, AgTech, EdTech, Robotics as well as adjacencies within Venture Capital and Private Equity. Occam helps build leadership teams that meet the demands of the rapidly developing, competitive, and challenging industries it serves. Occam Global recruits leading C-Suite executives and board members for the most exciting and innovative clients across the world with a specific focus on the UK, Continental Europe, the US, and Asia.